KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)

Completed · Phase 4

Conditions studied: Chronic Kidney Diseases, Iron Deficiency Anemia

In brief

The objectives of this study are to assess the long-term efficacy and safety of different dose regimens of KRX-0502 in the treatment of iron deficiency anemia (IDA) in adult subjects with non-dialysis dependent chronic kidney disease (CKD).

Key facts

Study ID
NCT03236246
Run by
Keryx Biopharmaceuticals
People needed
206
Starts
2017-08-15
Expected to finish
2019-09-27
Last updated by the study team
2021-03-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.